The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
A 62-year-old woman has been found alive more than a week after she vanished while on a hiking trip.
The first African American actor to play the lead role in Les Misérables on Broadway has died, aged 21.
Crisis talks are to be held on the future of curry houses as cheap supermarket deals and immigration rules threaten the £4 billion industry.